VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Have had one prior platinum-based chemotherapy     │ Have had one prior platinum-based chemotherapy     │     100 │
│ regimen for the treatment of primary disease       │ regimen for the treatment of primary disease       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At least 4 weeks since last surgery or radiation   │ At least 4 weeks since last surgery or radiation   │     100 │
│ therapy                                            │ therapy                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have had a treatment-free interval of greater │ Must have had a treatment-free interval of greater │     100 │
│ than 6 months following response to platinum       │ than 6 months following response to platinum       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ECOG performance status of 0,1, or 2               │ ECOG performance status of 0,1, or 2               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of child-bearing potential that do not       │ Women of child-bearing potential that do not       │     100 │
│ practice adequate contraception                    │ practice adequate contraception                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating                              │ Pregnant or lactating                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Received more than one primary chemotherapy        │ Received more than one primary chemotherapy        │     100 │
│ regimen                                            │ regimen                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant or previous malignancies with the      │ Concomitant or previous malignancies with the      │     100 │
│ exception of adequately treated basal cell or      │ exception of adequately treated basal cell or      │         │
│ squamous cell skin cancer, in situ cervical        │ squamous cell skin cancer, in situ cervical        │         │
│ cancer, incidental carcinoid, or other cancer from │ cancer, incidental carcinoid, or other cancer from │         │
│ which the patient has been disease free for 5      │ which the patient has been disease free for 5      │         │
│ years                                              │ years                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active uncontrolled infection requiring            │ Active uncontrolled infection requiring            │     100 │
│ antibiotics                                        │ antibiotics                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent severe medical problems unrelated to    │ Concurrent severe medical problems unrelated to    │     100 │
│ the malignancy which would limit full compliance   │ the malignancy which would limit full compliance   │         │
│ with the study                                     │ with the study                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Received radiation to more than 10% of bone        │ Received radiation to more than 10% of bone        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment with topotecan or gemcitabine      │ Prior treatment with topotecan or gemcitabine      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypersensitivity to camptothecin or nucleoside     │ Hypersensitivity to camptothecin or nucleoside     │     100 │
│ analogues                                          │ analogues                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of an investigational agent within 30 days     │ Use of an investigational agent within 30 days     │     100 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                  │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════╪═════════╡
│ Must be FEMALE                    │ Pregnant or lactating                          │      17 │
├───────────────────────────────────┼────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Use of an investigational agent within 30 days │      41 │
╘═══════════════════════════════════╧════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 91.125
OverAll Ratio: 94.5625
